News

The tie up allows Pall to use the services of Avacta and market joint services in North America, and in other regions globally where Avacta is not currently

Following the investment by Quintiles, Kareus plans to submit an investigational new drug (IND) application for KU-046, a first-in-class new chemical entity discovered by Kareus for the treatment

VX-770 is a medicine in development for people with cystic fibrosis who are 6 years or older and have at least one copy of the G551D mutation. The

The new patent entitled, ‘Deep Draw Container Forming Method,’ covers manufacturing technology of VersiDoser and VRx2 drug and biologic delivery systems. Mystic claims its delivery platforms offer preservative

The trial evaluated patients who were divided into three arms: placebo, low dose and high dose EPI-A0001. In the trial, EPI-A0001 improved neurological function as assessed by the

The launch follows the approval from the US Food and Drug Administration for Letrozole 2.5mg Tablets’ abbreviated new drug application (ANDA). Letrozole tablets are bioequivalent to Novartis’ Femara,

Hong Yu has succeeded Taylor Guo, who has left the company for personal reasons. Yu said he would like to thank Taylor Guo for his commitment and dedication

Three controlled clinical trails comprising 1,239 adult patients have established the efficacy of ezogabine as adjunctive therapy in partial onset seizures. The companies plan to introduce the product

Adcetris is an antibody-drug conjugate (ADC) constituting an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a synthetic drug, monomethyl auristatin E (MMAE) using Seattle Genetics’ proprietary